Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of Stryker Corp. stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $118.22, for a total transaction of $1,418,640.00. Following the transaction, the director now directly owns 193,142 shares in the company, valued at $22,833,247.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Stryker Corp. (NYSE:SYK) traded up 0.40% during midday trading on Tuesday, reaching $120.16. 135,133 shares of the company’s stock traded hands. Stryker Corp. has a 52-week low of $86.68 and a 52-week high of $123.55. The firm has a market capitalization of $44.99 billion, a P/E ratio of 27.35 and a beta of 0.86. The stock’s 50 day moving average price is $115.16 and its 200 day moving average price is $114.69.
Stryker Corp. (NYSE:SYK) last released its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The firm earned $2.83 billion during the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the company posted $1.25 earnings per share. The business’s revenue for the quarter was up 17.1% compared to the same quarter last year. On average, equities research analysts anticipate that Stryker Corp. will post $5.78 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Prudential PLC raised its position in Stryker Corp. by 17.3% in the first quarter. Prudential PLC now owns 77,352 shares of the medical technology company’s stock valued at $8,299,000 after buying an additional 11,432 shares in the last quarter. Nuveen Asset Management LLC raised its position in Stryker Corp. by 0.9% in the first quarter. Nuveen Asset Management LLC now owns 25,177 shares of the medical technology company’s stock valued at $2,701,000 after buying an additional 217 shares in the last quarter. National Pension Service raised its position in Stryker Corp. by 4.2% in the first quarter. National Pension Service now owns 190,643 shares of the medical technology company’s stock valued at $20,454,000 after buying an additional 7,658 shares in the last quarter. Bayesian Capital Management LP bought a new position in Stryker Corp. during the first quarter valued at about $264,000. Finally, Zurich Insurance Group Ltd FI raised its position in Stryker Corp. by 47.6% in the first quarter. Zurich Insurance Group Ltd FI now owns 48,105 shares of the medical technology company’s stock valued at $5,161,000 after buying an additional 15,510 shares in the last quarter. Hedge funds and other institutional investors own 75.29% of the company’s stock.
A number of research firms have recently issued reports on SYK. Canaccord Genuity reiterated a “buy” rating and set a $130.00 price objective on shares of Stryker Corp. in a research note on Sunday, July 24th. SunTrust Banks Inc. began coverage on shares of Stryker Corp. in a research note on Thursday, October 13th. They set a “buy” rating and a $140.00 price objective on the stock. BMO Capital Markets upgraded shares of Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price objective on the stock in a research note on Tuesday, November 1st. They noted that the move was a valuation call. Oppenheimer Holdings Inc. set a $122.00 price objective on shares of Stryker Corp. and gave the company a “hold” rating in a research note on Sunday, October 30th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and set a $119.00 price objective on shares of Stryker Corp. in a research note on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $121.27.
About Stryker Corp.
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.